Neurochemical properties of BDNF-containing neurons projecting to rostral ventromedial medulla in the ventrolateral periaqueductal gray by Jun-Bin Yin et al.
ORIGINAL RESEARCH ARTICLE
published: 20 November 2014
doi: 10.3389/fncir.2014.00137NEURAL CIRCUITS
Neurochemical properties of BDNF-containing neurons
projecting to rostral ventromedial medulla in the
ventrolateral periaqueductal gray
Jun-Bin Yin1†, Huang-Hui Wu2†, Yu-Lin Dong1†, Ting Zhang1, Jian Wang1, Yong Zhang1, Yan-Yan Wei1,
Ya-Cheng Lu1, Sheng-Xi Wu1, Wen Wang1* and Yun-Qing Li1*
1 Department of Anatomy and K.K. Leung Brain Research Centre, Preclinical School of Medicine, Fourth Military Medical University, Xi’an, China
2 Department of Anesthesiology, Fuzhou General Hospital Affiliated to Fujian Medical University, Fuzhou, China
Edited by:
Takao K. Hensch, Harvard
University, USA
Reviewed by:
Samuel S.-H. Wang, Princeton
University, USA
Andrew Paul Tosolini, University of
New South Wales, Australia
*Correspondence:
Wen Wang and Yun-Qing Li,
Department of Anatomy and K.K.
Leung Brain Research Centre,
Preclinical School of Medicine,
Fourth Military Medical University,
No. 169 West Changle Road, Xi’an
710032, China
e-mail: wangwen@fmmu.edu.cn;
deptanat@fmmu.edu.cn
†These authors have contributed
equally to this work.
The periaqueductal gray (PAG) modulates nociception via a descending pathway that relays
in the rostral ventromedial medulla (RVM) and terminates in the spinal cord. Previous
behavioral pharmacology and electrophysiological evidence suggests that brain-derived
neurotrophic factor (BDNF) plays an important role in descending pain modulation, likely
through the PAG-RVM pathway. However, detailed information is still lacking on the
distribution of BDNF, activation of BDNF-containing neurons projecting to RVM in the
condition of pain, and neurochemical properties of these neurons within the PAG. Through
fluorescent in situ hybridization (FISH) and immunofluorescent staining, the homogenous
distributions of BDNF mRNA and protein were observed in the four subregions of PAG.
Both neurons and astrocytes expressed BDNF, but not microglia. By combining retrograde
tracing methods and formalin pain model, there were more BDNF-containing neurons
projecting to RVM being activated in the ventrolateral subregion of PAG (vlPAG) than
other subregions of PAG. The neurochemical properties of BDNF-containing projection
neurons in the vlPAG were investigated. BDNF-containing projection neurons expressed
the autoreceptor TrkB in addition to serotonin (5-HT), neurotensin (NT), substance P (SP),
calcitonin gene related peptide (CGRP), nitric oxide synthase (NOS), and parvalbumin
(PV) but not tyrosine decarboxylase (TH). It is speculated that BDNF released from
projection neurons in the vlPAG might participate in the descending pain modulation
through enhancing the presynaptic release of other neuroactive substances (NSs)
in the RVM.
Keywords: periaqueductal gray (PAG), rostral ventromedial medulla (RVM), brain-derived neurotrophic factor
(BDNF), projection neurons, neurochemical properties
INTRODUCTION
In the central nervous system, there are multiple neural networks
that are involved in pain modulation. The periaqueductal gray
(PAG)-rostral ventralmedial medulla (RVM) pathway is located
in a pivotal site in the descending pain modulatory system includ-
ing descending inhibition (DI) and descending facilitation (DF)
and also recognized as the site of action for analgesic agents
including opioids, cyclooxygenase inhibitors, and cannabinoids
(Yaksh et al., 1976; Hohmann et al., 2005; Leith et al., 2007).
Now it is generally accepted that the PAG is organized primar-
ily as four longitudinal columns along the rostrocaudal extent:
the dorsomedial (dmPAG), dorsolateral (dlPAG), lateral (lPAG),
and ventrolateral (vlPAG) subregion of PAG, which is recognized
as a heterogenous structure (Paxinos and Watson, 2005). Each
column has its own unique neuroanatomical and functional char-
acteristics (Bandler and Shipley, 1994; Behbehani, 1995; Bandler
and Keay, 1996). There are various neuroactive substances (NSs)
involved in DI or DF in the PAG. Different NSs can produce
different effects, and sometimes, the same NS induces both DI
and DF (Millan, 2002).
Recent evidence indicates that brain-derived neurotrophic fac-
tor (BDNF), a member of the neurotrophin family that is essential
for neuronal survival during development, axonal growth, neuro-
transmission (Birling and Price, 1995; Lewin and Barde, 1996),
and contributes to synaptic plasticity in the adult mammalian
brain (Thoenen, 1995), could produce both DI and DF in the
PAG (Siuciak et al., 1994; Frank et al., 1997; Guo et al., 2006;
Zhang et al., 2013). It has been demonstrated that not only do the
mRNA and protein of BDNF exist in the PAG (Ceccatelli et al.,
1991; Conner et al., 1997), but some BDNF-containing neurons
are also observed to project to RVM in the PAG (Guo et al., 2006).
The effects of BDNF aremediated through its binding to TrkB and
subsequent activation of downstream signaling pathways (Huang
and Reichardt, 2003). The BDNF-TrkB signaling pathway has
been shown to play a critical role in activity-dependent synaptic
plasticity underlying learning and memory through both presy-
naptic and postsynaptic mechanisms (Schinder and Poo, 2000;
Lu, 2003; Carvalho et al., 2008). It is also demonstrated that
BDNF could enhance the release of peptides from the primary
afferent fibers (Berninger and Poo, 1996; Malcangio et al., 1996).
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There is evidence indicating that BDNF could facilitate pain
through inducing the phosphorylation of N-methyl-D-asparate
(NMDA) receptors (Guo et al., 2006), down-regulating the K+-
Cl− cotransporter (Zhang et al., 2013) and modulating 5-HT
(Wei et al., 2010) postsynapticaly in the RVM.
It is important and necessary to investigate the topographic
distribution and cell population of BDNF in the PAG for inter-
preting its related function. The distribution pattern of BDNF-
containing projection neurons within the PAG is still unclear.
It is necessary to clarify them, because only some subregions of
the PAG participate in descending pain modulation (Chen et al.,
2008, 2013). In addition, even though infusing BDNF into PAG
or RVM can inhibit or facilitate pain (Siuciak et al., 1994; Guo
et al., 2006), there is no direct evidence to demonstrate that BDNF
is involved in the descending pain modulation through PAG-
RVM pathway. Also, there has been no report to investigate the
NSs’ expression of BDNF-containing projection neurons in the
PAG for underling the presynaptic mechanism participating in
the descending pain modulation. We therefore observed the neu-
rochemical properties of BDNF-containing projection neurons in
the vlPAG.
MATERIALS AND METHODS
ANIMALS
Adult male Sprague Dawley rats (250–300 g) were used in all
experiments. Eighteen rats were divided into 4 groups. Group 1
(3 rats) was used for FISH and double-immunofluorescent histo-
chemical staining. Group 2 (6 rats) was used for simple retrograde
tracing investigation and triple-immunohistochemical staining.
Group 3 (6 rats) was used for combining retrograde tracing and
formalin pain model and triple-immunohistochemical staining.
Group 4 (3 rats) was used for injecting normal saline into the
hindpaw. Rats were housed in a temperature-controlled environ-
ment on a 12 h light/dark cycle with access to food and water
ad libitum. The experiments were approved by the Institutional
Animal Care and Use Committee of the Fourth Military Medical
University (Xi’an, China), and the ethical guidelines to investigate
experimental pain in conscious animals.
FLUORESCENT IN SITU HYBRIDIZATION (FISH) HISTOCHEMISTRY
Under deep anesthesia with 2% sodium pentobarbital
[100mg/kg, intraperitoneal (i.p.)], three rats were perfused
through the ascending aorta with 200ml of normal saline
containing 0.1% (v/v) diethyl pyrocarbonate (DEPC, DH098-
2, Genview, Houston, TX) followed by 500ml of 2% (w/v)
paraformaldehyde containing 15% (v/v) saturated picric acid in
0.1M phosphate buffer (PB, pH 7.4). The brain was post-fixed
for 24 h in the same fixative at 4◦C, and transferred to 30% (w/v)
sucrose in 0.1M PB containing 0.1% (v/v) DEPC for 48 h at
4◦C. The brain stem was cut into 25μm thick coronal sections
on a freezing microtome (Leica CM1800; Heidelberg, Germany)
at −20◦C. All processes of FISH were performed following our
previous publications (Ge et al., 2014; Kou et al., 2013) and
according to the manual (Boster Inc.; Wuhan, China) by using
the DNA probe sequences antisense as 5′-GGCGC CACTC
CGACC CCGCC CGCCG TGGGG AGCTG-3′ and 5′-AAGTG
TAATC CCATG GGTTA CACGA AGGAA GGCTG-3′ for BDNF
mRNA. Briefly, free-floating sections were hybridized for 24 h
at 50◦C with digoxigenin-labeled DNA probe for BDNF in a
hybridization buffer. After washes, the hybridized sections were
incubated overnight at room temperature (RT) with peroxidase-
conjugated antidigoxigenin sheep antibody (11-426-338-910;
Roche Diagnostics, Basel, Switzerland) in 0.1M Tris-HCl (pH
7.5)-buffered 0.9% (w/v) saline containing 1% blocking reagent
(TSB). To visualize the signals for BDNF mRNA efficiently, we
performed the biotinylated tyramine-glucose oxidase amplifi-
cation method. Subsequently, the sections were incubated with
10μg/ml Alexa594-conjugated streptavidin (S-32356; Invitrogen,
Eugene, OR) in TSB for 3 h and then incubated for 15min with
DAPI (1:5,000, D1306, Molecular Probes, Eugene, OR, USA)
diluted in 0.01M phosphate-buffered saline (PBS, pH 7.4) and
underwent three more wash steps followed by mounting and
coverslipping on microscope slides.
Negative controls were treated with hybridization buffer with-
out BDNF DNA probe and the other procedures were unchanged
following the previous instructions. No hybridization signals were
detected in these sections.
INTRA-RVM STEREOTAXIC MICROINJECTIONS
The injection procedures have been described in our previous
study (Chen et al., 2013). In brief, animals were anesthetized
with 2% sodium pentobarbital (40mg/kg, i.p.). A midline open-
ing was made on the skull with a dental drill to insert a glass
micropipette (tip diameter 40–60μm) connected with a microsy-
ringe (1μl, Hamilton, NV, USA) into the target site. The incisor
bar was set at 2.9–3.5mm below the horizontal plane passing
through the interaural line. A volume of 0.06μl of 4% Fluoro-
Gold (FG; Fluorochrome; 80014; Biotium; Hayward, CA, USA)
dissolved in normal saline, was pressure-injected into nucleus
raphe magnus (NRM), the major part of RVM, according to
the following coordinates: 10.5mm caudal to Bregma, midline
and 10.3mm ventral to the surface of the cranium (Paxinos and
Watson, 2005). Each injection was made slowly over 10min and
the injection needle was kept in place for another several minutes.
After being kept alive for 5–7 days, the rats were re-anesthetized
with 2% sodium pentobarbital (40mg/kg, i.p.) and injected with
10μl of 1% colchicines for efficiently detecting the peptide neuro-
transmitters into the lateral ventricle (0.48mm caudal to Bregma,
1.6mm right to midline and 3.6mm ventral to the surface of the
cranium) and survived for another 24 h before perfusion.
FORMALIN PAIN MODEL
In order to test whether the BDNF-containing PAG-RVM path-
way was activated by noxious stimuli, formalin pain model was
used. After the rats acclimated to a dimly-lit and soundproof test-
ing chamber for about 20min, they were briefly anesthetized with
isoflurane. Then 50μl of 5% formalin solution (dissolved in nor-
mal saline) or 50μl of normal saline (served as sham control)
was subcutaneously (s.c.) injected into the right hindpaw using
a microsyringe attached to a 30-G needle after 6–8 d of the FG
injection. After s.c. formalin injection, the rats were taken into
the observing cage (sound-attenuated, clear Perspex, 25 × 25 ×
40 cm) and a video recording was performed for 60min, as
described in previous study (Bai et al., 2012). The pain behaviors
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were manually recorded with a stop watch by retrieving spon-
taneous flinches or lickings of the injected hindpaw from the
recorded videos. At 2 h after s.c. formalin injection, rats were
perfused and used for the later morphological studies.
PERFUSION AND TISSUE PREPARATION
Under deep anesthesia with 2% sodium pentobarbital
(100mg/kg, i.p.), rats were perfused through the ascending
aorta with 200ml of normal saline followed by 500ml of 2%
(w/v) paraformaldehyde and 15% (v/v) saturated picric acid in
0.1M PB. Then, the brain was removed, immersed in the same
fixative for 4 h at 4◦C, and transferred to 30% (w/v) sucrose in
0.1M PB until sink. After being embedded in an inert mounting
medium (OCT; Tissue-Tek; Sakura; Torrance, CA, USA), coronal
sections of the brain containing PAG or RVM were cut at 25μm
thickness using a freezing microtome and were collected into
dishes containing 0.01M PBS. The sections containing PAG or
RVM regions in the first dish were mounted onto gelatin-coated
glass slides, air dried and coverslipped with a mixture of 50%
(v/v) glycerin and 2.5% (w/v) triethylenediamine (anti-fading
agent) in 0.01M PBS and then observed using a fluorescence
microscope (Olympus BX-60; Tokyo, Japan) for investigating the
injection or projection sites.
DOUBLE- OR TRIPLE-LABELING IMMUNOFLUORESCENCE (IF)
HISTOCHEMISTRY
Following our previous protocol (Li et al., 1996), the sections
underwent double- or triple-labeling IF using different antibod-
ies in the combinations and dilutions showing in Table 1. Briefly,
free-floating sections containing PAG were blocked for 30min
with 10% normal donkey serum (NDS) in 0.01M PBS. Then
the sections were subjected to the following sequential incu-
bations with: (1) primary antibodies in the antibody dilution
medium (0.01M PBS containing 5% (v/v) NDS (PBS-NDS),
0.3% (v/v) Triton X-100, 0.05% (w/v) NaN3 and 0.25% (w/v)
λ-carrageenan) overnight at RT and then 72 h at 4◦C; (2) a mix-
ture of secondary antibodies in PBS-NDS for 3 h at RT and then
10 h at 4◦C; (3) fluorescence isothiocyanate (FITC)-conjugated
avidin in PBS containing 0.3% Triton X-100 (PBS-X, pH 7.4), for
2 h at RT.
Some other sections were used as controls by replacing the pri-
mary antibodies with the combinations of normal rabbit, mouse,
rat, goat or guinea pig serum according to the species of primary
antibodies used, while keeping the other conditions unchanged.
(For BDNF, see Supplementary Figure 1).
The antibodies used in the current study were rabbit anti-
BDNF antiserum (ab6201; Abcam, Cambridge, MA, USA);
mouse anti-NeuN antiserum (MAB377; Millipore, Billerica,
MA, USA); mouse anti-GFAP antiserum (MAB3402; Millipore);
mouse anti-OX42 antiserum (CBL1512; Millipore); guinea pig
anti-FG antiserum (NM-101; PROTOS BIOTECH CORP, New
York, NY, USA); goat anti-5-HT antiserum (20079; ImmunoStar,
Houston, Texas, USA); rat anti-NT antiserum (NP-103; PROTOS
BIOTECH CORP); rat anti-SP antiserum (MAB356; Millipore);
goat anti-CGRP antiserum (ab36001; Abcam); mouse anti-
NOS antiserum (N-2280; Sigma, St. Louis, MO, USA); mouse
anti-PV antiserum (P-3171; Sigma); mouse anti-TH antiserum
(T-2928; Sigma); goat anti-TrkB antiserum (sc-20542; Santa
Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-FOS
antiserum (ab11959; Abcam); biotin-donkey anti-rabbit IgG
(AP182F; Millipore); Alexa594-donkey anti-mouse IgG (A21203;
Invitrogen, Carlsbad, CA, USA); Alexa594-goat anti-guinea pig
IgG (A-11076; Invitrogen); Alexa594-donkey anti-goat IgG (A-
11058; Invitrogen); Cy3-donkey anti-rat IgG (AP189c;Millipore);
Alexa647-donkey anti-guinea pig IgG (AP193SA6; Millipore);
FITC-Avidin (A-2001; Vector, Burlingame, CA, USA).
OBSERVATION OF THE FLUORESCENT-POSITIVE PROFILES
After the IF or FISH, the sections were observed and images were
captured under confocal laser scanning microscope (FV1000;
Table 1 | Antibodies used in each group.
Antigen Primary Antibodies Secondary Antibodies Tertiary Antibodies Groups
Double Staining BDNF and Rabbit anti-BDNF (1:200) Biotin-donkey anti-rabbit (1:500) FITC-Avidin (1:1,000)
NeuN or Mouse anti-NeuN (1:2,000) Alexa594-donkey anti-mouse (1:500) BDNF/NeuN
GFAP or Mouse anti-GFAP (1:4,000) Alexa594-donkey anti-mouse (1:500) BDNF/GFAP
OX42 or Mouse anti-OX42 (1:200) Alexa594-donkey anti-mouse (1:500) BDNF/OX42
FG Guinea Pig anti-FG (1:300) Alexa594-goat anti-Guinea pig (1:500) BDNF/FG
Triple Staining BDNF and Rabbit anti-BDNF (1:200) Biotin-donkey anti-rabbit (1:500) FITC-Avidin (1:1,000)
FG and Guinea Pig anti-FG (1:300) Alexa647-donkey anti-Guinea pig (1:500)
5-HT or Goat anti-5-HT (1:500) Alexa594-donkey anti-goat (1:500) BDNF/FG/5-HT
NT or Rat anti-NT (1:200) Cy3-donkey anti-rat (1:500) BDNF/FG/NT
SP or Rat anti-SP (1:200) Cy3-donkey anti-rat (1:500) BDNF/FG/SP
CGRP or Goat anti-CGRP (1:200) Alexa594-donkey anti-goat (1:500) BDNF/FG/CGRP
NOS or Mouse anti-NOS (1:3,000) Alexa594-donkey anti-mouse (1:500) BDNF/FG/NOS
PV or Mouse anti-PV (1:1,000) Alexa594-donkey anti-mouse (1:500) BDNF/FG/PV
TH or Mouse anti-TH (1:5,000) Alexa594-donkey anti-mouse (1:500) BDNF/FG/TH
TrkB or Goat anti-TrkB (1:100) Alexa594-donkey anti-goat (1:500) BDNF/FG/TrkB
FOS Mouse anti-Fos (1:500) Alexa594-donkey anti-mouse (1:500) BDNF/FG/FOS
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Olympus) with appropriate filters for FITC (excitation 492 nm,
emission 520 nm), Cy3 (excitation 552 nm, emission 565 nm),
Alexa594 (excitation 590 nm, emission 618 nm), or Alexa647
(excitation 647 nm, emission 666 nm). For counting the num-
bers of labeled cells, a careful focus through the thickness of all
sections determined that the immunolabeling had penetrated the
whole thickness of sections, and only did the neuronal cell bod-
ies, in which the maximum of the nuclei could be observed with
obvious light emission, be counted. In addition, the sections were
carefully moved across the stage and analyzed from left to right.
CELL COUNTING
To investigate the percentage of mRNA signals among DAPI pos-
itive cells, image analysis software ImageJ (National Institutes
of Health, Bethesda, MD) was utilized. This module quantified
the number of BDNF mRNA signals per section by thresholding
mRNA signals above background levels and by using DAPI stain-
ing to differentiate between nuclei. Each subregions of PAG was
manually outlined for quantification. To examine the distribution
of BDNF protein in the PAG, three frames were randomly chosen
(100 × 100 μm) in each subregion of PAG per section following
the previous study (Tasset et al., 2012). In each area, the total
number of BDNF-immunoreactive (-ir) neurons was counted.
Sections were captured digitally with 20 X objective by confocal
laser microscope. For analyzing the coexpression of BDNF and
other NSs and related proteins, we counted the immunopositive
neurons separately in total area of each subregion then calcu-
late the percentages of double- or triple-labeling neurons. Counts
were performed by a blinded microscopist. Cell count estimates
were presented as mean±SD (mean number of total labeled cells
per rat). To evaluate variations in data, a one-way analysis of
variance (One-Way ANOVA) was used. The level of statistical
significance was set at P < 0.05.
RESULTS
DISTRIBUTIONS OF BDNF mRNA AND PROTEIN IN THE PAG
Obvious gray matters could be observed around the aqueduct in
the Nissl-stained sections, in which there were lots of cell bod-
ies (Figures 1A,B). Combining the Nissl staining and the atlas of
the rat brain, the four subregions of PAG were outlined man-
ually in different segments: dmPAG, dlPAG, lPAG, and vlPAG
(Paxinos and Watson, 2005). We performed fluorescent in situ
hybridization (FISH) and immunofluorescence (IF) histochem-
istry to investigate the topographic distributions of BDNFmRNA
and protein in the PAG. BDNF mRNA signals were observed
throughout the PAG. DAPI was used to identify the location of
BDNF mRNA, and all BDNF mRNA-labeled cells had a marked
nucleus (Figures 2A–G). There was no difference on the distri-
bution of BDNF mRNA signals, by calculating the percentage
of them among DAPI+ cells [Figure 2H: dmPAG, 56.4 ± 8.8%;
dlPAG, 43.8 ± 3.9%; lPAG, 57.1 ± 12.6%; vlPAG, 52.9 ± 8.7%;
One-Way ANOVA, F(3, 8) = 1.373, P > 0.05]. The distribution
pattern of BDNF protein was similar to that of the mRNA in
the PAG (Figures 5A,D,G). The BDNF-immunoreactive (ir) neu-
ronal densities among the four subregions were similar [Figure 2
I: dmPAG, 7.7 ± 0.4; dlPAG, 6.8 ± 0.1; lPAG, 7.6 ± 1.1; vlPAG,
7.8 ± 0.6 per 100 × 100 μm2; One-Way ANOVA, F(3, 8) = 1.573,
P > 0.05]. These results indicate that BDNF mRNA and protein
distribute homogenously in the four subregions of PAG.
CELL POPULATIONS OF BDNF IN THE PAG
The presence of BDNFmRNA and protein in the PAG inspired us
to investigate the cell expression patterns of BDNF. The neuronal
and glial expressions of BDNF were explored by markers for dif-
ferent cells. Double labeling between BDNF and NeuN (Neuronal
Nuclei), as well as between BDNF and GFAP (Glial Fibrillary
Acidic Protein) could be observed in the PAG. But double label-
ing between BDNF and OX42 was not observed (Figure 3). These
results indicate that not only neurons (NeuN positive cells), but
also astrocytes (GFAP positive cells) express BDNF in the PAG.
Microglia (OX42 positive cells) never shows any BDNF staining.
Given the existence of BDNF-containing neurons in the PAG, we
wanted to know whether these neurons could project to RVM
involved in the descending pain modulation.
DISTRIBUTION OF NEURONS PROJECTING TO RVM IN THE PAG
First, the distribution of neurons projecting to RVM in the PAG
was examined by using retrograde tracing method. Retrogradely
labeled neurons were observed in the PAG after injecting FG into
RVM. The representative section showed the injection site was
located on the midline and centered in the nucleus raphe mag-
nus (NRM) (Figure 4A). FG labeling was observed in dmPAG,
lPAG, and vlPAG. FG-labeled neurons were much less com-
mon in dlPAG and dorsal raphe nucleus (DR) (Figures 4B–D).
Most FG-labeled neurons were small to medium sized and had
fusiform, triangular, oval and/or multipolar shapes. Pressure
injection of FG into RVM also gave rise to a large number of ret-
rogradely labeled neurons in the midbrain adjacent to PAG, such
as cuneiform nucleus, mesencephalic trigeminal nucleus, ventral
tegmental nucleus, and external cortex of the inferior colliculus.
In addition, the numbers of projection neurons in the four
subregions of PAG were counted. The numbers of FG-labeled
neurons were 644.0 ± 45.0, 58.0 ± 19.1, 825.3 ± 39.1, and
930 ± 62.6, respectively in dmPAG, dlPAG, lPAG, and vlPAG of
each rat. There was significant difference among the four sub-
regions [One-Way ANOVA, F(3, 8) = 231.8, P < 0.0001]. There
were more projection neurons in the dmPAG, lPAG, and vlPAG
than those in the dlPAG (Figure 4E).
DISTRIBUTION OF BDNF-CONTAINING PROJECTION NEURONS IN THE
PAG
Next, double-labeling IF was used to investigate whether these
projection neurons expressed BDNF. BDNF-ir neurons, FG
labeled neurons and BDNF/FG-ir neurons were all observed in
the PAG (Figure 5). The numbers of BDNF/FG-ir neurons in the
dmPAG, dlPAG, lPAG, and vlPAG were 452.0 ± 59.1, 36.3 ± 6.5,
582.3 ± 43.3, and 756.7 ± 34.3, respectively. There was signif-
icant difference among the four subregions [One-Way ANOVA,
F(3, 8) = 170.4, P < 0.0001]. The number of BDNF/FG-ir neu-
rons in the vlPAG was more than those in the other subre-
gions (Table 2). Respectively, 18.7 ± 1.4%, 11.4 ± 1.3%, 24.1 ±
0.2%, and 24.0 ± 0.5% of BDNF-ir neurons were BDNF/FG-
ir neurons in the dmPAG, dlPAG, lPAG, and vlPAG. There was
also significant difference among the four subregions [One-Way
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FIGURE 1 | Nissl staining shows the PAG and its four subregions
in the midbrain at Bregma −7.92mm. The green dashed lines are
manually outlined based on the atlas of the rat brain. Scale bar =
200μm in (A), 100μm in (B). Aq, aqueduct; dlPAG, dorsolateral
subregion of the PAG; dmPAG, dorsomedial subregion of the PAG;
DR, dorsal raphe nucleus; lPAG, lateral subregion of the PAG; mlf,
medial longitudinal fasciculus; vlPAG, ventrolateral subregion of the
PAG.
ANOVA, F(3, 8) = 110.0, P < 0.0001]. The proportion in the
vlPAG was higher than those in the dmPAG or dlPAG (Table 2).
The proportions of BDNF/FG-ir neurons to FG labeled neurons
were 70.6 ± 3.0%, 65.8 ± 8.4%, 70.6 ± 5.4%, and 81.5 ± 0.9%.
Similar to above results, there was significant difference among
the four subregions [One-Way ANOVA, F(3, 8) = 4.8, P < 0.05].
And the proportion in the vlPAG was higher than that in the
dlPAG (Table 2). According to these results, it is supposed that
there is factually a PAG-RVM BDNF-containing pathway and
BDNF-containing projection neurons are likely to be distributed
over most but not all of the PAG.
ACTIVATION OF BDNF-CONTAINING PROJECTION NEURONS IN THE
FORMALIN MODEL
Finally, we sought to identify whether these BDNF-containing
projection neurons in the PAG were involved in pain modulation.
The activation of these neurons was indicated by FOS expres-
sion after formalin was injected into the hindpaw. Two hours
after formalin injection, FOS labeling neurons were character-
ized with densely stained nuclei, which were round or oval with
unstained cytoplasm. In many regions of the midbrain related
to pain modulation, FOS could also be found, such as DR,
median raphe nucleus (MnR), paramedian raphe nucleus (PMR),
interpeduncular nucleus (IPN), superior and inferior colliculus
(Supplementary Figure 2). In the PAG, FOS was also observed,
especially in the caudal vlPAG. The numbers of BDNF/FG/FOS
labeled neurons were 12 ± 5.2, 0, 48 ± 5.2, 74.7 ± 4.1 and
the portions of these neurons to BDNF/FG labeled neurons
were 5.3 ± 1.9%, 0, 17.4 ± 1.3%, 20.6 ± 0.9% in the dmPAG,
dlPAG, lPAG, vlPAG, respectively. There were significant differ-
ences among the four subregions [One-Way ANOVA, F(3, 8) =
198.4, P < 0.0001; F(3, 8) = 181.8, P < 0.0001] (Figure 6). In
addition, the number of BDNF/FG/FOS labeled neurons and the
activated percentage in the vlPAG were more than those in the
other subregions. In the sections from control rats, the distri-
bution of FOS labeled neurons was sparse and only scattered
FOS was found in the PAG. And less than 1% of BDNF-ir neu-
rons were labeled with FOS in the PAG. It is suggested that
BDNF-containing projection neurons in the PAG play a role in
the formalin-induced hindpaw pain and vlPAG might play a
more important part than the other subregions. So our attentions
were focused on the BDNF-containing projection neurons in the
vlPAG.
NEUROCHEMICAL PROPERTIES OF BDNF-CONTAINING PROJECTION
NEURONS IN THE vLPAG
It is important for comprehending the roles of BDNF in the
descending pain modulation to investigate chemical features
of BDNF-containing projection neurons in the vlPAG. Triple-
labeling IF was used to examine the colocalization of BDNF,
FG and serotonin (5-HT), neurotensin (NT), substance P (SP),
calcitonin gene related peptide (CGRP), nitric oxide synthase
(NOS), parvalbumin (PV), or tyrosine decarboxylase (TH) that
characterized BDNF-containing projection neurons in the vlPAG
(Figures 7, 8). 5-HT-ir neurons were observed mainly in the DR
and vlPAG, and diffused distribution in the dmPAG and lPAG. SP-
ir neurons could be observed in the lPAG, CnF, vlPAG and DR,
especially in the DR and lPAG. NT-ir neurons and fibers were
observed around the PAG, of which DR, lPAG, and vlPAG had
the most numbers of NT-ir neurons. Numerous CGRP-ir neu-
rons that were fusiform, spheroidal, and triangular in shape were
observed, mostly in the caudal vlPAG and DR in the rostral PAG.
And BDNF-containing projection neurons expressing 5-HT, NT,
SP and CGRP could also be observed (Figure 7).
There were numerous neurons expressing NOS in the dlPAG,
vlPAG, and caudal DR. PV-expressing neurons were observed
in all four subregions of the PAG and DR. The TH-ir neu-
rons mainly distributed in the DR, and small numbers extended
into the vlPAG of the rostral portion. BDNF-containing pro-
jection neurons expressing NOS and PV could be observed,
while triplely labeled BDNF/FG/TH neurons were not found
(Figure 8).
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FIGURE 2 | Distributions of BDNF mRNA and protein in the four
subregions of PAG. (A–C) Low magnification FISH photomicrographs show
the signals for BDNF mRNA visualizing with Alexa594 (red) and DAPI (blue) in
the PAG. (D–G) High magnification images also show the signals for BDNF
mRNA and DAPI. The framed area in (F) is magnified in (G). Arrows indicate
cells expressing BDNF mRNA. (H) Percentages of BDNF mRNA signals
among DAPI+ cells in the four subregions of PAG. (I) Numbers of BDNF-ir
neurons per 100 × 100 μm2 in the four subregions of PAG. There was no
significant difference between columns in (H) and (I). Scale bars = 50μm in
(C) (applies A–C); 20μm in (F) (applies D–F); 10μm in (G).
The numbers and percentages of these triple- and double-
labeling neurons were shown in Table 3. The numbers of triple-
labeling neurons were 280.0 ± 37.7, 366.7 ± 45.4, 309.3 ± 12.2,
304± 27.7, 106.7± 9.2, and 212.7± 12.7 for 5-HT, NT, SP, CGRP,
NOS, and PV. Among BDNF/5-HT-ir, BDNF/NT-ir, BDNF/SP-ir,
BDNF/CGRP-ir, BDNF/NOS-ir, BDNF/PV-ir neurons, there were
70.4 ± 6.2%, 34.2 ± 5.7%, 39.6 ± 5.6%, 33.7 ± 3.6%, 30.9 ±
3.9%, 69.1 ± 2.4% neurons that projected to RVM, respectively.
In the vlPAG, 38.8 ± 6.8%, 47.0 ± 6.5%, 44.8 ± 2.9%, 42.7 ±
3.5%, 14.7 ± 0.9%, 28.5 ± 1.6% of BDNF-containing projection
neurons expressed 5-HT, NT, SP, CGRP, NOS, PV, respectively.
BDNF could be expressed in 84.0 ± 4.9%, 88.2 ± 2.9%, 87.3 ±
2.6%, 85.5 ± 4.8%, 69.3 ± 8.9%, 70.9 ± 6.3% of 5-HTergic,
NTergic, SPergic, CGRPergic, NOS-containing, PV-containing
projection neurons in the vlPAG.
EXPRESSION OF TrkB IN BDNF-CONTAINING PROJECTION NEURONS
Respecting BDNF-containing projection neurons expressed 5-
HT, NT, SP, CGRP, NOS, or PV. Besides, BDNF has the ability
to enhance the release of neurotransmitters. We next examined
whether BDNF-containing projection neurons expressed BDNF
receptors, TrkB. Using the same approach, TrkB-containing neu-
rons were observed in all of the four subregions of PAG and
DR. In the vlPAG, there were 443.3 ± 45.0 BDNF/TrkB/FG-ir
neurons, 70.8 ± 6.3% of BDNF/TrkB-ir neurons projected to
the RVM, 61.7 ± 5.9% of BDNF-containing projection neurons
expressed TrkB, and 81.2 ± 1.3% of TrkB-containing projec-
tion neurons expressed BDNF. These results indicate that BDNF
and its receptor TrkB coexist in the same PAG-RVM projection
neurons.
DISCUSSION
The present data enhance our understanding of the PAG-RVM
pathway underlying the descending pain modulation, includ-
ing descending inhibition and facilitation. Specifically, the data
demonstrate that (i) in the PAG, BDNF homogeneously dis-
tributes in the four subregions and is mainly expressed in neurons
and astrocytes; (ii) a subset of PAG neurons expressing BDNF
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FIGURE 3 | Fluorescent photomicrographs show both neurons and
astrocytes express BDNF, but not microglia. (A–D) Colocalization of
BDNF (green) and NeuN (red), NeuN is the marker for neurons. (E–H)
Colocalization of BDNF (green) and GFAP (red), GFAP is the marker for
astrocytes. (I–L) Expression of BDNF (green) and OX42 (red), OX42 is
the marker for microglia. The framed areas in (C,G,K) are magnified in
(D,H,L) respectively. Arrows indicate the colocalization of BDNF/NeuN (D)
and BDNF/GFAP (H); arrowheads indicate the single expression of NeuN
(D) or OX42 (L). Scale bars = 20μm in (K) (applies A–C, E–G, I–K);
10μm in (H) (applies D,H,L).
are involved in the formalin pain model especially in the vlPAG,
which also projecte to RVM; (iii) in the vlPAG, BDNF-containing
neurons projecting to RVM express 5-HT, NT, SP, CGRP, NOS,
or PV; (iv) BDNF-containing projection neurons also express its
own receptors, TrkB. It is speculated that BDNF released from
projection neurons in the vlPAG participate in the descending
pain modulation likely through regulating the presynaptic release
of NSs in the RVM.
DISTRIBUTIONS AND CELL POPULATIONS OF BDNF IN THE PAG
Immunohistochemistry and in situ hybridization in bright-field
method have been used to show that neurons in the PAG and asso-
ciated regions express BDNF (Ceccatelli et al., 1991; Conner et al.,
1997). However, these studies have not specifically focused on the
PAG and have, therefore, not considered the precise distribution
of BDNF in the four subregions of PAG. We used both FISH and
IF to detect the mRNA and protein in the PAG and compared
the distributions of BDNF in the four subregions. About half of
the DAPI+ cells in the PAG expressed mRNA of BDNF, and there
were 7.5 ± 0.7 BDNF-ir neurons per 100 × 100 μm2. There were
no significant differences on the distributions of BDNF mRNA
and protein among the four subregions of PAG. These homo-
geneous distributions reflect the multifunctionality of BDNF in
the mammalian brain, including neuronal survival during devel-
opment, axonal growth, neurotransmission, and modulation of
synaptic plasticity (Birling and Price, 1995; Thoenen, 1995; Lewin
and Barde, 1996). Our report now clarifies which cells express
BDNF in the PAG.
Neurons, astrocytes, and microglia all express BDNF in other
different regions of brain (Martinowich et al., 2007; Boyadjieva
and Sarkar, 2013; Degos et al., 2013; Gomes et al., 2013;
Quesseveur et al., 2013), but microglia do not express BDNF
in the PAG. What is the reason of expressing cellular differ-
ences, especially between astrocytes and microglia in differ-
ent regions? Heterogeneity of BDNF expression might confer
a regional specificity on cellular expressing of BDNF for dif-
ferent functions. For example, BDNF released from astrocytes
might locally modulate local circuits that participate in the
descending targets of the PAG. The neuronal expression of
BDNF illustrated the probability that BDNF-containing neurons
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FIGURE 4 | Distribution of retrogradely labeled neurons in the PAG
after FG was injected into the raphe magnus nucleus. (A) Fluorescent
photomicrograph shows FG injection site in the raphe magnus nucleus
and its adjacent regions. Scale bar = 200μm. (B–D) Fluorescent
photomicrographs show the general distributing patterns of FG
retrogradely labeled neurons from the RVM in the four subregions of the
PAG. FG labeled neurons were observed in the dmPAG (B), lPAG (C),
vlPAG (D). In the dlPAG (B) and DR (D), few FG labeled neurons were
seen. Scale bar = 100μm. (E) Summary of the numbers of FG labeled
neurons in four subregions of the PAG. (Mean ± SD) N.S. no significant,
∗∗ P < 0.01, ∗∗∗ P < 0.001, One-Way ANOVA, Dunnett’s Test. 4V, 4th
ventricle; cic, commissure of the inferior colliculus; CnF, cuneiform
nucleus; DR, dorsal raphe nucleus; NGC, gigantocellular reticular nucleus;
Py, pyramidal tract; RVM, rostroventral medial medulla.
could project to the RVM and participate in descending pain
modulation.
DISTRIBUTION AND ACTIVATION OF BDNF-CONTAINING PROJECTION
NEURONS IN THE PAG
In the present study as well as in previous reports using differ-
ent retrograde tracers including horseradish peroxidase (HRP)
and colloidal gold-labeled wheat germ agglution conjugated to
HRP (WGA-HRP) (Gallager and Pert, 1978; Carlton et al., 1983),
neurons retrogradely labeled from the RVM were distributed
throughout the dmPAG, lPAG, vlPAG, and were relatively less
common in the dlPAG and DR. In the present study, projection
neurons in the PAG expressed BDNF, consistent with a previous
study using cholera toxin subunit B (CTB) as retrograde tracer
(Guo et al., 2006). However, the coexpression of BDNF and CTB
was only investigated in the vlPAG and lPAG. In addition to this,
the numbers of BDNF/FG-ir neurons in the dlPAG and dmPAG
were counted in our study. Although FG has the similar efficiency
of labeling to CTB used for retrograde tracing (Spike et al., 2003),
we detected more BDNF-ir neurons due to different antibody
against BDNF used in our work. Therefore higher percentages
of BDNF-ir projection neurons among FG labeled neurons were
observed, 81.5 ± 0.9% and 70.6 ± 5.4% vs. 63 ± 4% and 41 ±
6%, in the vlPAG and lPAG respectively.
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FIGURE 5 | Fluorescent photomicrographs show the distribution of
BDNF-ir neurons and FG labeled neurons in the PAG after FG
was injected into the raphe magnus nucleus. The distributions of
BDNF-ir (green) and/or FG labeled (red) neurons are shown in the
dmPAG (A–C), lPAG (D–F), and vlPAG (G–I). (J–M) High magnification
images show the colocalization of BDNF and FG in the PAG. Arrows
indicate the merged BDNF/FG neurons, arrowheads indicated the
BDNF-ir neurons, and double arrowheads indicate the FG labeled
neurons. Scale bars = 50μm in (I) (applies A–I); 20μm in (L) (applies
J–L); 10μm in (M).
Table 2 | Numbers of neurons labeled with BDNF and/or FG in four subregions of the PAG.
dmPAG dlPAG lPAG vlPAG
Neurons singly labeled with BDNF only 1960.7±83.2 282.3± 25.5 1848.7± 98.7 2392.0±86.7
Neurons singly labeled with FG only 191.0±49.8 18.7± 4.2 242.3± 48.2 172.3±18.0
Neurons dually labeled with BDNF and FG 452.0±59.1a1 36.3± 6.5a2 582.3± 43.8a3 756.7±34.3
Neurons labeled with BDNF 2412.7±141.7 318.7± 30.7 2411.0± 168.1 3148.7±117.1
Neurons labeled with FG 643.0±108.3 55.0± 4.4 824.7± 26.7 929.0±52
Ration of dually labeled neurons in BDNF neurons 18.7±1.4%b1 11.4± 1.3%b2 24.1± 0.2%b3 24.0±0.5%
Ration of dually labeled neurons in FG neurons 70.6±3.0%c1 65.8± 8.4%c2 70.6± 5.4%c3 81.5±0.9%
Data are shown as Mean ± SD, N = 3.a1,a2 P < 0.0001, a3 P < 0.001, b1,b2 P < 0.0001, b3 P > 0.05,c1,c3 P > 0.05, c2 P < 0.05, One-Way ANOVA, Dunnett’s Test.
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FIGURE 6 | Activation of BDNF-containing projection neurons in the
PAG after formalin injection. BDNF-containing (green) projection neurons
(blue) could express FOS (red). Arrows indicate BDNF/FG/FOS merged
neurons (D); filled arrowheads indicate neurons singlely expressing BDNF
(A); unfilled arrowheads indicate neurons singlely expressing FOS (B);
unfilled arrows indicate neurons singlely labeled by FG (C); double filled
arrowheads indicate colocalization of BDNF and FOS (D); double unfilled
arrowheads indicate BDNF-ir and FG labeled neurons (D). The framed
areas in (D) are magnified in (E). Counting the numbers of activated
BDNF-containing projection neurons (BDNF/FG/FOS-ir neurons) (F) and the
percentages of these neurons among BDNF-containing projection neurons
(G) in the four subregions of PAG. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗
P < 0.001, One-Way ANOVA, Dunnett’s Test. Scale bars = 20μm in (D)
(applies A–D); 10μm in (E).
Even though it has been reported that exogenously applied
BDNF into the PAG produces analgesia (Siuciak et al., 1994;
Frank et al., 1997) or inflammatory pain induces increase in
BDNF expression in PAG neurons (Guo et al., 2006), there
is no direct evidence for activation of BDNF-containing pro-
jection neurons in the PAG. Furthermore, which subregions
of PAG BDNF-containing projection neurons are involved in
descending pain modulation? In our investigation, the number
of activated BDNF-containing projection neurons and the per-
centage of them among BDNF-containing projection neurons
in the vlPAG were higher than those in the other subregions
in the formalin pain model. In the previous studies (Morgan,
1991; Guo et al., 2006), the vlPAG has been shown to be pivotal
in modulation of morphine-induced analgesia and descending
facilitation in the inflammatory pain. The vlPAG is thought
to be the most important part for descending pain modu-
lation and great parts of modulatory effects in other subre-
gions are achieved by changing the activity of neurons in the
vlPAG, although analgesic effect can be fulfilled through stimu-
lating the four subregions of PAG (Bandler and Depaulis, 1991;
Millan, 2002). It should also be noticed that BDNF-containing
projection neurons were activated in dmPAG and lPAG. Those
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FIGURE 7 | Fluorescent photomicrographs show the expression of
neurotransmitters (5-HT, NT, SP, CGRP) in BDNF-containing projection
neurons in the vlPAG after FG was injected into the raphe magnus
nucleus. BDNF-containing (green) projection neurons (blue) could express
5-HT (A–E), NT (F–J), SP (K–O), CGRP (P–T) (red). Arrows indicate the
merged BDNF/FG/neurotransmitters, BDNF-ir projecting neurons expressing
5-HT (D), NT (I), SP (N), CGRP (S); filled arrowheads indicate singly BDNF-ir
(A,F,K,P) or FG labeled neurons (H,M); double filled arrowheads indicate
BDNF and 5-HT (D), NT (I), SP (N), CGRP (S) merged neurons; double
unfilled arrowheads indicate BDNF and FG merged neurons (D,I,N). The
framed areas in (D,I,N,S) are magnified in (E,J,O,T) respectively. Scale bars =
20μm in (S) (applies A–D,F–I, K–N, P–S); 10μm in (T) (applies E,J,O,T).
functional BDNF-containing projection neurons might be related
to fear and anxiety, and vocalization for pain rather than pain
modulation.
NEUROCHEMICAL PROPERTIES OF BDNF-CONTAINING PROJECTION
NEURONS IN THE vlPAG
There are lots of NSs involved in the PAG-RVM descending
pathway, which is thought to be one reason for complexity of
descending pain modulatory system (Millan, 2002; Fu et al.,
2010; Bowman et al., 2013). Glutamate and GABA are the most
widely distributed neurotransmitters in the central nervous sys-
tem. There are numerous neurons containing WGA-HRP and
glutamate in the PAG after injecting theWGA-HRP into the NRM
(Beitz, 1990). Although the numbers and proportions of double
labeled neurons were not reported in that study, approximately
40% of myelinated axons in the NRM contained glutamate-
like immunoreactivity and glutamate-ir was also observed in
unmyelinated axons. GABAergic neurons are small in size, make
up about 15–20% of all PAG neurons (Barbaresi and Manfrini,
1988; Reichling and Basbaum, 1990). However, only 1.5% of
all retrogradely labeled neurons from the NRM in the PAG
are also GABA-ir (Reichling and Basbaum, 1990). It is nec-
essary that the coexpression of glutamate or GABA/BDNF/FG
needed to have been investigated. However, using antibodies we
failed to detect glutamate, GABA, or markers for them in the
PAG. In the future, we hope to observe the coexpression of
BDNF/glutamate or GABA through ISH or using transgenic ani-
mals. There are also other NSs in the PAG, including enkephalin,
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FIGURE 8 | Fluorescent photomicrographs show the expression of NOS,
PV, TH, and TrkB in BDNF-containing projection neurons in the vlPAG
after FG was injected into the raphe magnus nucleus. BDNF-containing
(green) projection neurons (blue) could express NOS, PV, and TrkB, but not TH
(red). Arrows indicate the triply labeled neurons, BDNF-ir projecting neurons
expressing NOS (D), PV (I), and TrkB (S); filled arrowheads indicate singly
BDNF- (A,F,K,P) or NOS- (B) or TH-ir (L) or FG (C,H,M,R) labeled neurons;
double filled arrowheads indicate BDNF and TH (N) merged neurons; double
unfilled arrowheads indicate BDNF and FG (D,I,N,S) merged neurons; filled
and unfilled arrowheads indicate FG and TrkB merged neurons (S). The
framed areas in (D,I,N,S) are magnified in (E), (J,O,T) respectively. Scale bars
= 20μm in (S) (applies A–D, F–I, K–N, P–S); 10μm in (T) (applies E,J,O,T).
SP, somatostatin, galanin, vasoactive intestinal polypeptide, neu-
ropeptide Y, CGRP, 5-HT, NT, NO, dopamine, cholecystokinin,
and acetycholine, etc. (Smith et al., 1994; Millan, 2002). However,
there is not one review summarizing the neurochemical proper-
ties of PAG and those proportions. For these reasons, we chose
those that had been investigated more involved in the pain mod-
ulation. Moreover, the percentages of BDNF/FG/NSs-ir neurons
among the BDNF/FG-ir neurons were not low in our present
investigation. For other NSs that were not investigated in our
sudy, some were concerned less, such as vasoactive intestinal
polypeptide, some were not involved in the PAG-RVM path-
way, such as cholecystokinin (Beitz et al., 1983), some were
thought involved in other functions of PAG, such as acetycholine
(Deolindo et al., 2011). Of course, the NSs investigated in our
study are a part of all NSs involved in the PAG-RVM pathway.
More studies about other NSs are indeed to be carried out in
the future.
The NSs-ir neurons had a similar distribution as previous
studies (Beitz, 1982b,a; Smith et al., 1994; Chen et al., 2003;
Abrams et al., 2004; Fu et al., 2010). Some of these neurons can
inhibit and/or facilitate pain, leading to analgesia and/or hyper-
algesia. Increasing 5-HT synthesis facilitates analgesia, whereas
decreasing 5-HT synthesis or blocking 5-HT-receptor-mediated
transmission attenuates analgesia (Basbaum and Fields, 1984;
Stamford, 1995). Neurokinin-1 receptor (NK-1R)-ir neurons in
RVM are modulated by SP-ir efferent fibers from the PAG (Zeng
et al., 1991; Chen et al., 2013), and is essential for the full
expression of descending pain modulation (De Felipe et al., 1998;
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Bester et al., 2001). Dose response analyses revealed that NT
produced intensive response at lower dose in addition to analgesia
at higher doses following intra-RVM administration (Fang et al.,
1987; Urban and Smith, 1993). The hindpaw withdrawal latency
to nociceptive stimulation increases significantly after intra-RVM
administration of CGRP, which can be antagonized by its receptor
antagonist CGRP8-37 (Huang et al., 2000).
Some NSs are difficult to examine directly. An alternate
approach is to examine key enzymes that synthesize or other-
wise mark the presence of those NSs. NO is produced from
L-argine by NOS, and distributed in the PAG (Onstott et al.,
1993; Fu et al., 2010). NO in the vlPAG plays an important role
in visceral pain modulation and defensive reactions (Hamalainen
and Lovick, 1997; Rodella et al., 1998; Emmanouil et al., 2008).
PV, a calcium-binding protein, is involved in the control of
intracellular calcium homeostasis in inhibitory neurons (Nitsch
et al., 1990). In the PAG, inhibitory neurons make the funda-
ment for opioidergic descending analgesia (Park et al., 2010).
TH is the rate-limiting enzyme in the biosynthesis of cate-
cholamines, which is a marker of dopamine (Nagatsu et al.,
1964). PAG dopamine has a direct antinociceptive effect in addi-
tion to modulating the analgesic effect of morphine (Meyer
et al., 2009). Surprisingly, coexpression of BDNF/TH/FG was
not observed in the vlPAG. The possible reason was that few
TH-ir neurons could project from the vlPAG to the RVM,
which was coincidence with the previous study (Suckow et al.,
2013).
FUNCTIONAL CONSIDERATION OF BDNF-CONTAINING PROJECTION
NEURONS EXPRESSING TrkB IN THE vlPAG
Release of NSs, is modulated within milliseconds to seconds
through action on presynaptic receptors (Merighi, 2002; Carvalho
et al., 2008). Abundant mRNA and protein of TrkB are observed
in the central nervous sysem (Yan et al., 1997; King et al., 1999).
Full-length TrkB, BDNF, and SP or CGRP-ir central terminals of
primary afferent fibers make synapses with dendrites (Salio et al.,
2005). Employing patch-clamp recordings and calcium imaging,
it has been demonstrated that BDNF could enhance the release
of SP or CGRP by acting on the presynaptic TrkB receptors.
Effects can also be blocked by Trk antagonist K252a or anti-TrkB
antibody (Merighi et al., 2008). Although there were technical
limitations to investigate coexpression of BDNF/TrkB/NSs/FG in
the vlPAG, we infer the existence of at least some coexpression
for 5-HT, NT, SP and CGRP based on the high percentages of
triple-labeling neurons among BDNF/FG-ir neurons. It is pre-
sumed that there is the same mechanism for BDNF modulating
the presynaptic NSs’ release by binding presynaptic TrkB in the
PAG-RVM pathway.
Based on the distribution of TrkB in the PAG and the fact that
not only neurons but also astrocytes expressed BDNF and directly
infusing BDNF into the PAG produces analgesia (Siuciak et al.,
1994; Frank et al., 1997), it is presumed that there is a postsy-
naptic effect for BDNF. BDNF directly activates TrkB receptor
localized on neighboring or just the same neurons within the
vlPAG except for being transported anterogradely to RVM, as
BDNF released from microglia acts on TrkB localized on neu-
rons in the spinal cord (Coull et al., 2005). BDNF can increase
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the synthesis, transport, or release of NSs in the PAG, through
postsynaptic TrkB binding (Croll et al., 1994; Nawa et al., 1994).
In summary, BDNF is expressed mainly in neurons and astro-
cytes within the PAG. There are amounts of BDNF-containing
projection neurons in the four subregions of PAG, however, these
neurons in the vlPAG are more activated in the formalin pain
model. Furthermore, the vlPAG BDNF-containing neurons pro-
jecting to RVM express 5-HT, NT, SP, CGRP, NOS, PV, and TrkB.
These findings suggest that BDNF released from the projection
neurons in the vlPAG regulates the release of NSs via the presy-
naptic TrkB. These NSs work together with BDNF participating
in the PAG-RVM descending pain modulation.
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